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Abstract
Background—The spectrum approach was used to examine contributions of comorbid symptom
dimensions of substance abuse and eating disorder to abnormal prefrontal-cortical and subcortical-
striatal activity to happy and fear faces previously demonstrated in bipolar disorder (BD).
Method—Fourteen remitted BD-type I and sixteen healthy individuals viewed neutral, mild and
intense happy and fear faces in two event-related fMRI experiments. All individuals completed
Substance-Use and Eating-Disorder Spectrum measures. Region-of-Interest analyses for bilateral
prefrontal and subcortical-striatal regions were performed.
Results—BD individuals scored significantly higher on these spectrum measures than healthy
individuals (p < 0.05), and were distinguished by activity in prefrontal and subcortical-striatal
regions. BD relative to healthy individuals showed reduced dorsal prefrontal-cortical activity to all
faces. Only BD individuals showed greater subcortical-striatal activity to happy and neutral faces.
In BD individuals, negative correlations were shown between substance use severity and right PFC
activity to intense happy faces (p < 0.04), and between substance use severity and right caudate
nucleus activity to neutral faces (p < 0.03). Positive correlations were shown between eating disorder
and right ventral putamen activity to intense happy (p < 0.02) and neutral faces (p < 0.03). Exploratory
analyses revealed few significant relationships between illness variables and medication upon neural
activity in BD individuals.
Limitations—Small sample size of predominantly medicated BD individuals.
Conclusion—This study is the first to report relationships between comorbid symptom dimensions
of substance abuse and eating disorder and prefrontal-cortical and subcortical-striatal activity to facial
expressions in BD. Our findings suggest that these comorbid features may contribute to observed
patterns of functional abnormalities in neural systems underlying mood regulation in BD.
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1. Introduction
Bipolar disorder (BD) is a most debilitating psychiatric disorder, with a high rate of late or
mis-diagnoses, often as unipolar depression (Bowden, 2001). The research agenda for DSM-
V emphasizes the need for a new classification system for all psychiatric disorders based upon
pathophysiologic and etiological processes (e.g. Phillips and Frank, 2006), that may represent
biomarkers of a disorder (e.g. Kraemer et al., 2002). For disorders such as BD, the identification
of these biomarkers would be a major step toward improving diagnostic accuracy (e.g. Hasler
et al., 2006). Functional neuroimaging can examine abnormalities that may reflect
pathophysiological neural mechanisms underlying core clinical features of psychiatric
illnesses. Several recent neuroimaging studies in adult BD reported inconsistent findings of
dysfunctional dorsal and ventral prefrontal-cortical and subcortical-striatal neural systems
implicated in mood-regulation. Specifically, patterns of increased amygdala and striatal, and
decreased dorsal pre-frontal-cortical (DPFC) activity to emotionally-salient stimuli, and during
cognitive control tasks have been shown (e.g. Green et al., 2007; Phillips et al., 2008a).
Although present studies in BD have focused on neural systems associated with mood-
regulation, they have largely ignored common disabling comorbid features that characterize
the disorder (Kupfer, 2005) and contribute to its psychopathology. The spectrum approach to
BD includes measures of lifetime experiences of symptoms, clinical features and
temperamental traits that aim to improve assessing the clinical phenotype of BD, and contains
an integrated view of common comorbidities (e.g. Cassano et al., 1999). Comorbid symptom
dimensions of BD are associated with more severe illness course, poorer treatment compliance
and worse outcomes related to suicide (Krishnan, 2005). They include substance abuse, eating
disorders, psychosis, obsessive-compulsive and anxiety symptoms (Krishnan, 2005). For
example, an increased risk for substance abuse has been observed in BD (e.g. Regier et al.,
1990), and is associated with more severe mood episodes and worse illness course (Nolen et
al., 2004). It may be explained in terms of self-medication, improving self-image, or alleviating
symptoms of anxiety (Sonne et al., 1994). Eating disorders, particularly binge eating or weight
gain, other than those associated with medication effects, are common in BD (e.g. Angst et al.,
2002).
There is increasing evidence of overlap between functional abnormalities in neural systems
implicated in BD and those associated with the above comorbid symptom dimensions. For
example, BD-like reduced activity in right dorsolateral prefrontal-cortical (DLPFC) regions
during decision making tasks have been demonstrated in currently dependant amphetamine
and opiate users (Ersche et al., 2005a,b), and in abstinent cocaine users (Bolla et al., 2003;
Yucel and Lubman, 2007). In contrast to findings in BD, decreased rather than increased ventral
striatal activity has been reported to formerly rewarding cues in detoxified alcoholics (Wrase
et al., 2007). These findings support the growing literature in substance abuse showing patterns
of decreased ventral striatal dopamine release also during pharmacologic challenge with
amphetamine (Martinez et al., 2005; Volkow et al., 2007a,b).
The overlap between neural systems underlying mood regulation and appetitive behaviors is
well documented (Beaver et al., 2006; Kaye, 2007). Abnormally increased striatal activity
during reward processing has been reported in eating-disordered individuals (Wagner et al.,
2007), similar to the patterns of elevated ventral striatal and amygdala activity observed in BD
adults (Green et al., 2007; Phillips et al., 2008a).
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The above findings suggest that dysfunctional prefrontal-cortical and subcortical-striatal neural
regions previously observed in BD may be a reflection, at least in part, of comorbid symptom
dimensions that characterize the illness. Using an implicit emotion labeling task associated
with subcortical limbic activity, we previously demonstrated, in a group of remitted BD
individuals, greater striatal activity to happy faces and decreased dorsal prefrontal-cortical
(DPFC) activity to both happy and fear faces (Hassel et al., 2008). In these BD individuals,
most common comorbid features were substance use and eating disorders, but the contribution
of these to abnormal prefrontal-cortical and striatal activity was unexamined. The present study
aimed to assess, in these remitted BD individuals, the relationship between comorbid symptom
dimensions of substance abuse and eating disorders, and patterns of abnormal prefrontal-
cortical and subcortical-striatal activity. Based on the above findings we hypothesized: (1)
Severity of comorbid symptom dimensions of substance abuse would be negatively associated
with both, the magnitude of striatal activity to happy faces, and the magnitude of DLPFC
activity, to happy and fear faces. (2) Severity of comorbid symptom dimensions of eating
disorders would be positively associated with the magnitude of amygdala and striatal activity
to happy faces.
2. Methods
2.1. Participants
Fourteen BD-subtype-I individuals (23–52 years; 63% female) from our previous sample
(Hassel et al., 2008) were recruited from Western Psychiatric Institute and Clinic, Mood
Disorders Treatment and Research Program, University of Pittsburgh. All were in remission
(DSM-IV criteria; Structured Clinical Interview for DSM-IV (SCID-I); First et al., 1995).
Euthymic status was defined, a-priori, as having been in remission for at least 2 months as
assessed by SCID and clinical interview. All BD individuals scored <10 on the Young Mania
Rating Scale (Young et al., 1978). Twelve BD individuals scored <7 on the Hamilton Rating
Scale for Depression (HRSD-25; Williams, 1988). Two scored <14 but were included because
clinical evaluation deemed them eligible based on their SCID interview (Table 1). Eight BD
individuals had comorbid diagnoses of eating (binge eating; n = 3) disorder and/or substance
abuse disorder (n = 7). Twelve BD individuals were taking medication for at least 1 month
prior to the study (Table 1). Additionally, recruited were 16 healthy individuals (18–52 years;
50% female) without current and lifetime personal (SCID-I criteria) or family history of
psychiatric disorders. Exclusion criteria included borderline personality disorder (SCID-II-
criteria); history of head injury or neurological disease; systemic medication, controlled and
uncontrolled medical illnesses, cognitive impairment (score <24 in the Mini-Mental State
Examination, Folstein et al., 1975); non-right handedness (per Annett, 1970) and failure to
meet MRI screening criteria (pregnancy, metallic fragments, cardiac pacemaker or
claustrophobia). Both groups had received a detailed assessment of comorbid symptom
dimensions using the spectrum questionnaires in our previous study (Hassel et al., 2008).
After complete description of the study, participants gave written informed consent. The
University of Pittsburgh's Institutional Review Board approved this study.
2.2. Spectrum questionnaires
Measures to assess lifetime prevalence of Substance Use and Eating Disorder were
administered to BD and healthy individuals. Validity and reliability of these measures have
been demonstrated (see Mauri et al., 2000; Sbrana et al., 2003, respectively for detail on each
measure). Questionnaires can be downloaded from http://www.spectrum-project.net.
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2.3. Paradigm
All participants completed two, 6 min event-related paradigms; viewing mild and intense happy
and fear faces from a standardized series (Young et al., 2002). Both paradigms included neutral
faces and a baseline fixation-cross. Participants judged each face's gender, an implicit emotion
processing task reliably associated with activity in subcortical-striatal emotion processing
regions (e.g. Surguladze et al., 2003, 2005). To determine overt emotion labeling accuracy,11
of the BD and 14 of the healthy individuals also performed an emotion labeling task outside
the scanner. For 45 faces depicting sadness, anger, fear, happiness, disgust or neutral
expressions (Lundqvist et al., 1998), participants had to choose corresponding emotion labels
from a list of these six options. Problems in accommodating entire scanning and offline
procedures in some BD and healthy individuals prevented these data being available for all
study participants.
2.4. Data acquisition
We collected neuroimaging data using a 3.0 Tesla Siemens Allegra MRI scanner at the
University of Pittsburgh/CMU Brain Imaging Research Center. Structural 3D Sagittal
MPRAGE images were acquired as follows:TE:2.48 ms, TR:1630 ms, Flip-angle 8°, FOV:200
mm, Slice thickness:1 mm, Matrix:256 × 256, 192 continuous slices. Mean blood oxygenation-
level-dependent (BOLD) images were acquired using a gradient-echo EPI sequence:33 axial
slices(3 mm thick, 0 mm gap; TR/TE = 2000/25 ms, FOV = 2400 mm, matrix = 64 × 64).
2.5. Imaging analyses
Data were pre-processed and analyzed using statistical parametric mapping software (SPM5;
http://www.fil.ion.ucl.ac.uk/spm). All data were first corrected for differences in acquisition
time between slices; realigned using the first slice as a reference and unwarped to correct for
static inhomogeneity of the magnetic field and movement by inhomogeneity interactions. They
were then co-registered with the subject's anatomical image, segmented, normalized to
standard MNI template, resampled to 3 × 3 × 3 mm voxels, and spatially smoothed with a
Gaussian kernel of 6 mm full-width at half-maximum.
A first-level fixed-effect model was constructed with three emotion intensities (neutral, mild,
intense) in both experiments (happy, fear) entered as separate conditions in an event-related
design with fixation-cross as baseline in the design matrix. Movement parameters from the
realignment stage were entered as covariates of no interest to control for participant movement.
Trials were modeled using the Canonical Haemodynamic Response Function. The three
intensities were then entered as separate t-contrasts into second-level analyses (intense >
baseline; mild > baseline; neutral > baseline).
A second-level random-effects group analysis was conducted on t-contrasts generated in the
previous single-subject analyses in a 2(group)-by-3(intensity)-repeated measures ANOVA for
each experiment. Between-group comparisons of activity to each intensity in predetermined
Regions-of-Interest (RoI) in each experiment were subsequently performed to examine main
effects of group and condition and group-by-condition interactions. RoIs were defined using
the Wake Forrest University (WFU)-Pickatlas (Maldjian et al., 2003). Neural regions were
included in which abnormally increased activity–bilateral amygdalae, striatum(caudate
nucleus, putamen), and abnormally decreased activity–DPFC, have previously been reported
in BD (Lawrence et al., 2004; Hassel et al., 2008). Brodmann Areas (BA) 8,9,10,11,24,25,46
and 47 were included in the prefrontal cortex (PFC) RoI. BOLD-signal in each RoI identified
in the above ANOVAs was extracted using MarsBar0.40-toolbox (Brett et al., 2002). Posthoc
analyses were performed using matched-pairs and independent t-tests, as appropriate, to further
examine main effects of group and condition, or group-by-condition interactions that emerged
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from above ANOVAs. Bonferroni-adjusted p-values (p = 0.05/(number of comparisons +
number of regions) controlled for multiple comparisons.
Relationships between spectrum measures and neural activity in RoIs to emotional expressions
were examined in post-hoc correlational analyses. For all above analyses we used the total
score generated for each spectrum measure, and an adjusted statistical threshold of p = 0.025
(p = 0.05/2), to control for two separate spectrum measure correlational analyses with each
RoI showing a significant interaction, main effect of group or condition in each experiment.
To determine the potential impact of medication and illness variables, we first computed total
medication load, employing a strategy reported previously (Hassel et al., 2008; Versace et al.,
2008; Phillips et al., 2008b). We used Pearson's correlations to examine associations between
total medication load, potential effects of illness duration or age-of-illness onset and magnitude
of BOLD-signal in each RoI showing a significant interaction, main effect of group or
condition. An adjusted statistical threshold p = 0.05/(number of comparisons) controlled for
multiple comparisons.
3. Results
3.1. Participants
BD and healthy individuals were gender-ratio-matched. There was no significant between-
group difference in age or weight (p > 0.05), although eight BD individuals had comorbid
eating disorders. IQ, estimated by North American Reading Test (NART; Blair and Spreen,
1989) differed between BD and healthy individuals, t = 2.364, p = 0.026 (Table 1). However,
there were no significant differences between groups for gender labeling accuracy performed
during the scan (p < 0.05), and only a trend towards significant differences for emotion labeling
accuracy in the offline task (see below). We nonetheless included IQ in exploratory
correlational analyses examining its potential effect upon neural activity.
3.2. Emotion labeling accuracy
There was a trend difference in offline facial emotion labeling accuracy between the two groups
(Mann-Whitney-U-Test = 45.5, z = −1.75, p = 0.08): healthy individuals (mean-accuracy: 82%)
were more accurate than BD individuals (mean-accuracy: 79%). We therefore included
emotion labeling accuracy in exploratory analyses examining potential effects of variables
other than spectrum measures of comorbid symptoms upon neural activity in BD.
3.3. Spectrum measures
The total score on each spectrum measure was obtained by adding up individual items of each
subdomain. For Mean, Standard Deviation, Minimum and Maximum scores for both spectrum
measures see Table 1. BD and healthy individuals differed significantly for total scores on
Substance Use (t (2,28) = −2.17, p = 0.038) and Eating Disorder Spectrum measures (t(2,28)
= −2.09, p = 0.05).
3.4. Neuroimaging data analyses
We first examined main effects of group and condition, and group-by-condition interactions,
upon neural activity in our RoIs for both experiments. We then explored relationships between
the two spectrum measures and neural activity in RoIs showing main effects and interactions
in each experiment.
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3.5. Facial expression experiment—happy
3.5.1. Right dorsal PFC—A significant main effect of group (F(1,84) = 12.89, p
(uncorrected) = 0.001,Cohen's d = 1.36) revealed significantly decreased right dorsal PFC
(middle frontal gyrus, BA8) activity in BD relative to healthy individuals to all three emotional
conditions (neutral:t(1,29) = 6.69, p = 0.015,Cohen's d = 0.97; mild:t(1,29) = 6.73, p =
0.015,Cohen's d = 0.98; intense:t(1,29) = 6.37, p = 0.018,Cohen's d = 0.96) (Fig. 1 A, B).
3.5.2. Right ventral putamen—There was a main effect of condition (intense versus mild
versus neutral faces, F(2,84) = 8.01, p(uncorrected) = 0.001, Cohen's d = 1.07) within the right
ventral putamen. Post-hoc analyses showed significant differences in all individuals between
intense and mild happy faces (t(1,29) = −4.146, p < 0.001;Cohen's d = 0.48), and between
intense happy and neutral faces (t(1,29) = −3.709, p < 0.005;Cohen's d = 0.45). Across both
groups, relative to baseline, decreased activity to intense happy (mean BOLD-change:−0.31),
but increased activity to mild happy (mean BOLD-change:0.39) and neutral faces (mean
BOLD-change:0.38) was observed.
To examine relationships between spectrum measures and neural activity specifically in BD,
we analysed neural activity in RoIs in each group separately. Relative to baseline, BD
individuals showed patterns of predominant increases in activity, while healthy individuals
showed decreases, or minimal increases, in activity to each emotional stimulus. BD individuals
showed significantly increased activity to mild happy (mean BOLD-change:0.87) compared
to intense happy faces (mean BOLD-change:0.187, t(1,13) = −2.716, p = 0.018; Cohen's d =
0.49),andneutral (meanBOLD-change:0.79)relative to intense happy faces (t(1,13) = −2.867,
p = 0.013;Cohen's d = 0.45). Healthy individuals showed significantly decreased activity to
intense (mean BOLD-change:−0.738) relative to mild happy (mean BOLD-change: −0.018,
t = (1,15) = −3.038, p = 0.008, Cohen's d = 0.49), and neutral faces (mean BOLD change:0.021,
t(1,15) = −2.525, p = 0.023;Cohen's d = 0.56). There was no significant difference in activity
to mild happy relative to neutral faces (Fig. 1 D, E).
3.5.3. Left caudate nucleus—There was a significant main effect of condition (intense
versus mild versus neutral faces, F(2,84) = 7.04, p(uncorrected)<0.001,Cohen's d = 1.01) in
the left caudate body. Post-hoc analyses revealed significantly decreased activity to intense
happy relative to neutral faces, and mild happy relative to neutral faces in both groups (t(1,29)
= −2.794, p = 0.009, t(1,29) = −2.847, p = 0.008), respectively. Considering each group
separately, significant differences in activity between intense happy and neutral, and mild
happy and neutral faces were observed only in BD individuals. They showed significantly
decreased caudate activity to intense happy (mean BOLD-change:−1.29) relative to neutral
(mean BOLD-change:−0.58, t(1,13) = −2.257, p = 0.042;Cohen's d = 0.61), and mild happy
(mean BOLD-change:−1.2 4), relative to neutral faces (t(1,13) = −3.002, p = 0.01;Cohen's d
= 0.75).
3.6. Facial expression experiment—fear
3.6.1. Dorsal PFC—There was a significant main effect of group (F(1,84) = 12.11, p
(uncorrected) = 0.001,Cohen's d = 1.32). BD, relative to healthy individuals, showed
significantly decreased right dorsal PFC activity to all three emotional intensities (neutral:t
(1,29) = 9.39, p = 0.005, Cohen's d = 1.16; mild:t(1,29) = 10.88, p = 0.003, Cohen's d = 1.25;
intense:t(1,29) = 7.42, p = 0.011,Cohen's d = 1.16; Fig. 1 A, C).
3.6.2. Putamen—There were no significant main effects of group or emotion-condition or
interactions between these.
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3.6.3. Bilateral caudate nucleus—There was a significant main effect of emotion-
condition within the left (F(2,84) = 13.15, p(uncorrected)<0.001,Cohen's d = 1.37) and the
body of right caudate nucleus (F(2,84) = 9.84, p(uncorrected)<0.001;Cohen's d = 1.19).
Post-hoc analyses revealed, within the left caudate nucleus, significantly decreased activity to
intense fear (mean BOLD-change:−1.643) versus neutral faces (mean BOLD-change:−0.566,
t(1,29) = −3.806, p = 0.001;Cohen's d = 0.65) and mild fear (mean BOLD-change:−1.781)
versus neutral faces (t(1,29) = −4.873, p<0.001;Cohen's d = 0.73) across both groups, similar
to findings in the happy condition. BD individuals showed significantly decreased activity to
intense fear (mean BOLD-change:−1.623) relative to neutral (mean BOLD-change:v0.306, t
(1,13) = −2.705, p = 0.018; Cohen's d = 0.74), and mild fear (mean BOLD-change:−1.436)
relative to neutral faces (t(1,13) = −2.8, p = 0.013;Cohen's d = 0.63). Healthy individuals
showed significantly decreased activity to mild fear (mean BOLD-change:−2.084) relative to
neutral faces (mean BOLD-change:−0.795, t = (1,15) = −3.944, p = 0.001, Cohen's d = 0.84),
and intense fear (mean BOLD-change:−1.660) relative to neutral faces (t(1,15) = −2.68, p =
0.017;Cohen's d = 0.55).
Within the right caudate body, post-hoc analyses revealed significantly decreased activity to
intense fear (mean BOLD-change:−1.21) versus neutral faces (mean BOLD-change: −0.553,
t(1,29) = −3.766, p = 0.001;Cohen's d = 0.39), and mild fear (mean BOLD-change: −1.571)
versus neutral faces (t(1,29) = −4.774, p<0.001;Cohen's d = 0.55). BD individuals showed
significantly decreased activity to intense fear (mean BOLD-change:−1.211) relative to neutral
(mean BOLD-change:−0.601, t(1,13) = −2.202, p = 0.046;Cohen's d = 0.3), mild fear (mean
BOLD-change:−1.922) relative to neutral faces, (t(1,13) = −3.649, p = 0.003;Cohen's d = 0.61),
and mild fear relative to intense fear faces (t(1,13) = +2.38, p = 0.033; Cohen's d = 0.33).
Healthy individuals, showed significantly decreased activity to mild fear (mean BOLD-change:
−1.2 6) relative to neutral (mean BOLD-change:−0.511, t = (1,15) = −3.201, p = 0.006, Cohen's
d = 0.49), and intense fear (mean BOLD-change:−1.214) relative to neutral faces (t(1,15) =
−3.061, p = 0.008;Cohen's d = 0.54).
3.6.4. Amygdala—There were no significant main effects of group or condition nor group
by condition interactions for happy nor fear faces.
3.7. Relationships between Spectrum Measures and Regions of Interest in BD
Significant and trend correlations between spectrum measures and activity in RoIs are
described below. The significance level was set at 0.05/2=0.025 to control for separate
analyses.
3.7.1. Happy—There was a trend negative correlation between total scores on the Substance
Use Spectrum and activity to intense happy faces within the right PFC (r = −0.557, p = 0.04).
There was a significant positive correlation between total scores on the Eating Disorder
Spectrum and activity to intense happy faces within the right ventral putamen (r = 0.603, p =
0.02), and a trend positive correlation between this spectrum measure and activity in this region
to neutral faces in the happy experiment (r = 0.572, p = 0.03) (Fig. 2 A–C).
3.7.2. Fear—There was a trend negative correlation between total scores on the Substance
Use Spectrum and activity to neutral faces in the fear experiment, within the right caudate body
(r = −0.575, p = 0.03; Fig. 2 D).
3.8. Relationships between illness history variables, IQ, task performance and RoIs
Main findings from correlational analyses between RoIs in which significant effects of group
and condition were demonstrated in both experiments, illness history measure (illness duration,
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age-of-illness onset) and medication load index, IQ and facial expression labeling accuracy
are described below. Significance levels were set at 0.05/5 = 0.01, to control for five separate
analyses including each variable in each RoI. Neither IQ nor task performance correlated with
illness history variables or neural activity within RoIs.
3.8.1. Happy—There was a trend positive correlation between illness duration and activity
to neutral faces within the left caudate nucleus (r = 0.599, p = 0.03). A trend negative correlation
was observed between age-of-illness onset and activity within this region to neutral faces (r =
−0.612, p = 0.03). There were trend and significant positive correlations between medication
load and activity within this left caudate region to mild happy and neutral faces (r = 0.599, p
= 0.04 and r = 0.691, p = 0.006), respectively.
3.8.2. Fear—There was a trend positive correlation between illness duration and activity to
neutral faces in the fear experiment within the right caudate region (r = 0.594, p = 0.03). A
trend negative correlation between age-of-illness-onset and activity to mild fear and neutral
faces within the right dorsal PFC (r = −0.6, p = 0.03, and r = −0.6, p = 0.04), respectively, and
significant and trend negative correlations between medication load and activity in this region
to mild fear and neutral faces (r = −0.7, p = 0.005; and r = −0.6, p = 0.04), respectively were
observed.
4. Discussion
To our knowledge, this is the first study examining the extent to which patterns of abnormal
activity in prefrontal-cortical and striatal regions to facial expressions of happiness and fear,
previously reported in remitted BD (Hassel et al., 2008; Lawrence et al., 2004; Malhi et al.,
2007), are associated with severity of comorbid symptom dimensions of substance abuse and
eating disorders. These comorbid illness features were endorsed by most BD individuals in
this study. Relative to healthy individuals, BD individuals had significantly higher scores on
both spectrum measures. Our findings largely support our main hypotheses regarding abnormal
patterns of dorsal prefrontal-cortical and subcortical-striatal (ventral putamen, caudate nucleus)
activity to emotional faces in BD. Specifically, in BD, relative to healthy individuals, we
showed decreases in activity within prefrontal-cortical regions to happy and fear faces of all
intensities, and increased activity in the right putamen to mild happy faces, although this did
not reach our stringent threshold for significance in post-hoc analyses. Our findings further
suggest that comorbid symptom dimensions of substance abuse and eating disorders may be
associated with these patterns of abnormal neural activity in BD.
Observed associations between substance abuse and neural activity in BD supported our
hypotheses. A trend negative correlation was demonstrated between mean BOLD signal within
the right dorsal PFC to intense happy faces and substance abuse as measured by the Substance
Use Spectrum questionnaire. Previous findings in substance abusers have shown decreased
DLPFC activity during decision-making tasks (Bolla et al., 2003; Ersche et al., 2005a,b), but
also lower activation within PFC regions during a facial matching task (Payer et al., 2008). A
negative correlation would indicate that those BD individuals who endorsed more items on the
Substance Use Spectrum would show stronger deactivation within PFC regions. This could
then be linked to stronger difficulties in integrating socio-emotional information and,
subsequently, emotion regulation. There was also a trend negative correlation between mean
BOLD signal within the right caudate nucleus to neutral faces in the fear condition and the
Substance Use Spectrum in BD. In this context, neutral faces were the more positive expression
displayed, and may have been perceived as potentially more rewarding or ambiguous
(Somerville et al., 2004). The negative relationship between caudate nucleus activity to these
potentially more rewarding stimuli and substance abuse severity in BD individuals may be
linked to previous findings of decreased rather than increased ventral striatal activity to
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formerly rewarding cues in detoxified alcoholics (Wrase et al., 2007). Clearly, these findings
require further investigation in larger groups during reward paradigms.
Reported associations between severity of eating disorder and neural activity in BD also
support our hypotheses. We showed a significant positive correlation between right putamen
activity to intense happy faces, and a trend positive correlation to neutral faces in the happy
context, and scores on the Eating Disorder Spectrum. While there was no overall significant
effect of group on right ventral putamen activity to faces in the happy experimental condition,
only BD individuals showed a pattern of predominant increases in activity, relative to baseline,
to happy and neutral faces. The positive correlation between activity in ventral putamen to
these faces and eating disorder severity supports previous findings in recovered anorexic
individuals, who show greater ventral striatum activity during reward processing (Wagner et
al., 2007). In healthy individuals, a network of interconnected brain regions of OFC, ventral
striatum, amygdala and midbrain regions have been implicated in food reward processing
(Beaver et al., 2006). In our study, happy faces may have been perceived as more rewarding,
particularly to BD individuals with eating comorbidities.
In contrast to increased ventral putamen activity during the happy experimental condition, we
showed that both BD and healthy individuals had decreased caudate nucleus body activity to
emotional, relative to neutral, faces in happy and fear conditions. We reported patterns of
deactivation in left-sided and bilateral caudate nuclei, relative to baseline, in happy and fear
conditions, respectively. These findings suggest differential roles of caudate nucleus and
ventral putamen during emotion processing, and support previous research indicating distinct
roles of ventral and dorsal striatum in affective versus cognitive/associative processing (e.g.
Haber et al., 2006). Our findings of overall deactivation in caudate nucleus body in happy and
fear conditions in both groups may, therefore, support this region's role in cognitive rather than
emotional processing. The association between substance abuse and decreased activity in this
region to neutral faces in the happy context in BD individuals, and the link with previous
findings in substance abusers during reward processing does, however, provide some support
for a role of this region in reward processing. Further examination of ventral and dorsal striatal
activity during reward and cognitive control paradigms will help clarify the potentially distinct,
or overlapping, roles of ventral and more dorsal striatal regions in emotional and cognitive
processing.
We explored potential influences of illness history variables and medication upon neural
activity. The major finding here pertained to activity in the dorsal PFC and medication. There
were significant and trend negative correlations between medication load and right dorsal PFC
activity to mild fear and neutral faces. This suggests a more abnormal pattern of activity in this
region in those BD individuals with greater medication load and, potentially, more severe
illness course. There were trend and significant positive correlations between medication load
and left caudate nucleus activity to mild happy and neutral faces, respectively. Again, in those
BD individuals taking larger numbers and/or doses of psychotropic medications a more
abnormal pattern of activity, i.e. reduced deactivation were observed.
For illness duration variables, trend positive correlations with activity in the left and right
caudate body to neutral faces in happy and fear conditions, respectively, were observed.
Conversely, a trend negative correlation between activity in the left caudate body and age-of-
illness-onset to neutral faces in the happy condition was also reported. Since BD, like healthy
individuals, showed left and right caudate body deactivation to all faces in both experimental
conditions, these findings suggest that longer illness duration may have been linked to reduced
deactivation, i.e. a more abnormal pattern of activity in these regions. Interestingly, earlier age-
of-illness onset was associated with greater, not reduced, dorsal PFC activity to neutral and
mild fear in BD. This suggests that the reduced PFC activity to emotional facial expressions
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in BD adults in the present and previous studies (Hassel et al., 2008; Lawrence et al., 2004;
Yurgelun-Todd et al., 2000) may be particularly evident in individuals with later rather than
earlier age-of-illness onset.
While it is not possible to determine cause and effect between medication load and illness
severity and/or duration, these findings, together with those of relationships between illness
duration and caudate nucleus activity are consistent with greater illness severity, reflected by
longer illness duration and greater medication load, being associated with more abnormal
patterns of PFC activity in BD. Our findings regarding effects of illness history variables and
medication load should be considered preliminary, given the exploratory nature of these
analyses. They indicate, however, the importance of examining relationships between illness-
history variables and patterns of neural activity in BD individuals in future studies.
To our knowledge, this is the first functional neuroimaging study to examine relationships
between patterns of abnormal activity in prefrontal cortical and striatal regions to facial
expressions of happiness and fear and severity of comorbid symptom dimensions of substance
abuse and eating disorders in BD. Nonetheless, the following limitations have to be noted. The
number of euthymic BD patients in this study is relatively small, so future studies should
examine these relationships in larger groups of euthymic BD individuals. Significant
differences in IQ were observed between BD and healthy individuals, yet task performances
did not differ significantly, nor did correlational analysis show that IQ confounded activity
within our predetermined RoIs. Additionally, nearly all BD individuals in this study were
taking psychotropic medication. While it remains difficult, and potentially unrepresentative of
the BD population at large, to limit studies solely to unmedicated BD individuals (Phillips et
al., 2008b), if possible, medicated and unmedicated BD individuals should be included in future
studies.
We present first evidence of relationships between comorbid symptom dimensions of substance
abuse, eating disorders, and patterns of dorsal-prefrontal and striatal activity to emotional facial
expressions in BD. Our findings highlight the importance of including these measures in future
neuroimaging studies to inform understanding of the contribution of comorbid symptom
dimensions to patterns of functional abnormalities in neural systems in individuals with this
debilitating psychiatric illness.
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Fig. 1.
(A) Locus of significant activity for main effect of group for the happy and fear face paradigm.
Activity is shown for right dorsal PFC, MNI: 24 18 39. Post-hoc analyses revealed that BD
relative to healthy individuals showed decreased activity in this region to all three expressions,
(B) intense, mild happy and neutral faces, (F(1,84) = 12.89, p(uncorrected)<0.001). (C) intense,
mild fear and neutral faces, F(1,84) = 12.11, p(uncorrected)<0.001). (D) Locus of significant
activity for main effect of condition for the happy face paradigm, (F(2,84) = 8.01, p
(uncorrected)<0.001). Activity is shown for right putamen MNI: 30–129. (E) Post-hoc analyses
revealed that BD relative to healthy individuals showed increased activity in this region,
particularly to mild happy, but also neutral faces.
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Fig. 2.
Correlational analyses: positive correlations between Eating Disorder Spectrum and activity
within right putamen to (A) intense happy faces and (B) neutral faces; negative correlations
between Substance Use Spectrum and (C) activity within right dorsal PFC to intense happy
faces and (D) activity within right caudate nucleus body to neutral faces in a fear context.
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Table 1
Demographic and clinical variables, information on Spectrum Measures and relevant statistics (mean, standard
deviation, minimum-maximum scores)
Bipolar individuals Healthy individuals Statistics
N 14 16 n/a
Handedness Right Right n/a
Gender (female; male) 8; 6 8; 8 X2 = 0.14; p =
0.73
Age in years (Mean±SD; range) 32.64 ± 9.92; 23–52 28.50 ± 9.28; 18–52 t = −1.18; p =
0.24
NART (Mean ± SD; range) 111.77 ± 8.85; 92–
121.58
118.08 ± 5.39; 101.11–125.14 t = 2.36*; p =
0.026
Illness duration in years (Mean ± SD;
range) year
11.69 ± 6.32; 2–26 n/a n/a
Age-of-Illness onset (Mean ± SD;
range)
22.00 ±8.99; 12–44 n/a n/a
HAM-D (version 25) (Mean ± SD;
range)
3.0 ± 4.843; 0–18 n/a n/a
YMRS (Mean ± SD; range) 1.54 ± 2.60; 0–9 n/a n/a
Spectrum measures
Eating disorder 42.57 ± 35.22; 17.00 ± 15.63; t = −2.19;
(Mean ± SD; minimum-maximum) 1–96 6–52 p = 0.04
Substance use 34.71 ± 27.20; 18.27±15.78; t = −2.17;
(Mean ± SD; minimum-maximum) 8–97 0–54 p = 0.04
Medication - BD individuals only
Mood-stabilizers Antipsychotics Antidepressants Anxiolytics
Name of medication; number of
bipolar individuals taking
1Lithium; n = 3 7Risperidone; n
= 2
15Bupropion; n =
1
10Lorazepam;
n = 3
6Valproate; n = 2 2Aripiprazole; n
= 6
12Sertraline; n = 1 4Clonazepam;
n = 1
5Lamotrigine; n = 1 11Quetiapine; n
= 1
9Paroxetine; n = 1
14Carbamazepine; n =
1
3Olanzapine; n =
1
13Venlafaxine; n
= 2
8Gabapentin; n = 1
Monotherapy N = 1 (1) N = 3 (2) N = 0 N = 0
Combination treatment
Mood-stabilizers and antipsychotic N = 1 (2 5 6)
Mood-stabilizers, antipsychotic,
antidepressant and anxiolytic
N = 1 (1 2 7 8 9 10)
Mood-stabilizers and antidepressant N = 2 (1 6 13)
Mood-stabilizers, antidepressant and
anxiolytic
N = 1 (1 2 7 8 9 10)
Antipsychotics and antidepressants N = 1 (11 12)
Antipsychotics and anxiolytics N = 2 (2 3 4 7 10)
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Illness history information (illness duration; age-of-illness onset; HAM-D and YMRS scores) and medication information for bipolar individuals. Names/
types of medication and the number of bipolar patients who took these combinations. Numbers in superscript denote types of medication taken in either
mono-therapies or combination treatment.
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